IPO Date: Dec 20 to Dec 24 2024
Listing Date: Dec 30 2024
1.Investment in one of our Subsidiaries, Havix Group, Inc. d/b/a Aavis Pharmaceuticals (“Havix”), to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in our Atlanta Facility.
2.Re-payment/pre-payment, in full or in part, of certain borrowings availed by our Company.
3.Investment in our Subsidiary, namely, Havix, for re- payment/pre-payment in full or in part, of certain borrowings availed by such Subsidiary.
4.Funding the working capital requirements of our Company.
5.Investment in our Subsidiaries, namely, Senores Pharmaceuticals Inc. (“SPI”) and Ratnatris Pharmaceutical Private Limited (“Ratnatris”) to fund their working capital requirements.
6.Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes.
...
minantly for the Regulated Markets across various therapeutic areas and dosage forms, with a presence in Emerging Markets. Our strength lies in identifying, developing and manufacturing a diverse range of specialty, underpenetrated and complex pharmaceutical products establishing us as a preferred partner to certain customers. Through data analytics, research, market assessment and experienced management, we strategically identify commercially underpenetrated molecules to launch products in the Regulated and Emerging Markets. We leverage our R&D capabilities to develop and manufacture a portfolio of differentiated complex pharmaceutical products. Our focus on quality and our ability to identify specialty and complex molecules has resulted in an extensive pipeline of curated complex products spanning diverse dosage forms and therapeutic domains, demonstrated through our partnerships in the Regulated Markets with prominent foreign and Indian pharmaceutical companies including Prasco LLC, Lannett Company Inc., Jubilant Cadista Pharmaceuticals Inc., Alkem Laboratories Limited, Sun Pharmaceuticals Industries Limited, Dr. Reddy’s Laboratories Inc. and Cipla USA Inc. Read More
Posted on Dec 19th
Zensar Technologies informs about press release
Posted on Dec 19th
Admach Systems coming with IPO to raise Rs 42.60 crore
Posted on Dec 19th
Winter session of Parliament ends, both Houses adjourned sine die
Posted on Dec 19th
Currency futures for December expiry trade stronger with 0.24% increase in OI
The issue size of Senores Pharmaceuticals Ltd. IPO is ₹317.49 - 333.71 crore.
The Senores Pharmaceuticals Ltd. IPO opens for subscription on 2024-12-20 and closes on 2024-12-24.
The price range of Senores Pharmaceuticals Ltd. IPO is ₹372.00 to ₹391.00.
The lot size of Senores Pharmaceuticals Ltd. IPO is 38 shares.
The registrar of Senores Pharmaceuticals Ltd. IPO is MUFG Intime India Pvt Ltd..
This content is for educational purpose only and the same should not be construed as investment advice. Bajaj Finserv Direct Limited shall not be liable or responsible for any investment decision that you may take based on this content.
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.